ERN-industry partnerships achieve what no single actor has the capabilities to tackle alone, such are the multifaceted challenges inherent in rare disease research.
On 24 September 2025, MEPs Stine Bosse (Renew Europe, Denmark) and András Kulja (EPP, Hungary) hosted a high-level conference in the European Parliament to explore how public-private partnerships in rare disease research can unlock new therapies and boost EU innovation and competitiveness.
By leveraging the expertise of ERNs, the capabilities of industry stakeholders, and the input of patient communities, these collaborations contribute not only to improved health outcomes for 27-36 million Europeans living with a rare disease, and also galvanise the EU’s competitiveness in the global life sciences arena.